Appier Inc. is a technology company that specializes in artificial intelligence solutions to enhance customer engagement for enterprises. Founded in 2012 and headquartered in Taipei, Taiwan, Appier offers a range of AI-driven products, including Aideal, which aids in accelerating purchase decisions; AIQUA, a platform for proactive customer engagement based on user behavior; AIXON, a data science platform that enriches customer data for better audience insights and predictive modeling; and CrossX, an AI-powered advertising solution designed for optimal campaign performance. The company serves approximately 1,000 global brands and agencies, facilitating real-time bidding, programmatic media buying, and deep learning capabilities to help businesses target and retain customers effectively. Appier operates in 14 markets across Asia, including major cities such as Singapore, Kuala Lumpur, Tokyo, and Sydney.
SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in oncology and hematology. The company is developing several anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma. Additional products in development include SyB L-1701 and SyB L-1702, which are various formulations of anti-cancer agents, and Rigosertib SyB-C-0501, an oral treatment in Phase I trials for solid tumors. SymBio is also exploring treatments for higher-risk myelodysplastic syndromes and infectious diseases with its SyB V-1901 antiviral drug. The company operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore, and was established in 2005.